Emilio Sacco

Prof. Dr. Emilio Sacco

Urology, Università Cattolica del Sacro Cuore, Rome, Lazio, Italy
orcid
Ass. Prof. of Urology, Head of Urology Dept

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2006 in BJU International
Verified
Journal Article
Closed access
PDF file
Emilio SaccoEmilio Sacco
Emilio Sacco
TPTommaso Prayer‐Galetti
Tommaso Prayer‐Galetti
FPFrancesco Pinto
Francesco Pinto
SFSimonetta Fracalanza
Simonetta Fracalanza
GBGiovanni Betto
Giovanni Betto
WAWalter Artibani
Walter Artibani

4 September 2012 in Therapeutic Advances in Urology
Verified
Journal Article
Open access
Emilio SaccoEmilio Sacco
Emilio Sacco
Riccardo BientinesiRiccardo Bientinesi
Riccardo Bientinesi
Mirabegron is a novel, once-daily, orally active, first-in-class, potent β3-adrenoceptor agonist recently approved by Food and Drug Administration for overactive bladder therapy. Phase II studies and four large-scale phase III multinational randomized, controlled trials have supported the efficacy and tolerability of mirabegron in the clinical trial setting of patients with overactive bladder for up to 12 weeks of therapy and in the long term (12 months). The reported incidence and severity of treatment-emergent and serious adverse effects were similar to antimuscarinics, but with a more than threefold lower incidence of dry mouth compared with tolterodine. However, the effects on the cardiovascular system, pharmacokinetic interactions with other drugs, and increased incidence of new malignant events will require careful evaluation in the near future.

1 May 2006 in Journal of Urology
Verified
Journal Article
Closed access
VFVincenzo Ficarra
Vincenzo Ficarra
FZFiliberto Zattoni
Filiberto Zattoni
WAWalter Artibani
Walter Artibani
AFAndrea Fandella
Andrea Fandella
GMGuido Martignoni
Guido Martignoni
Emilio SaccoEmilio Sacco
Emilio Sacco
In penile cancer the therapeutic benefits of early inguinal lymphadenectomy must be counterbalanced by the high rates of morbidity, postoperative complications and mortality. A relevant aim is optimizing the selection of the patients who could really have the highest survival advantage from inguinal lymphadenectomy, limiting the cases in which this surgery might be considered over treatment with a risk of severe complications. We generated a nomogram estimating the risk of pathological inguinal lymph node involvement according to clinical lymph node stage and pathological findings of the primary tumor. We retrospectively collected the clinical and pathological data of 175 patients who had undergone surgical therapy for squamous cell carcinoma of the penis from 1980 to 2002 at 11 urological centers in northeastern Italy. A logistic regression model was used to construct the nomogram. The presence of palpable groin lymph nodes and the histological findings of vascular and/or lymphatic embolization were important predictors of metastatic inguinal lymph node involvement. The nomogram predicting the risk of metastatic lymph node involvement showed a good concordance index (0.876) and good calibration. The clinical stage of groin lymph nodes and pathological findings of penectomy specimens allowed us to generate a nomogram to predict the probability of metastatic lymph node involvement in patients with squamous cell carcinoma of the penis. The statistical model showed an excellent ability to identify the patients with lymph node metastases and good calibration.

2 June 2005 in Cancer
Verified
Journal Article
Closed access
PDF file
VFVincenzo Ficarra
Vincenzo Ficarra
FZFiliberto Zattoni
Filiberto Zattoni
SCSergio Cosciani Cunico
Sergio Cosciani Cunico
TGTommaso Prayer Galetti
Tommaso Prayer Galetti
LLLucio Luciani
Lucio Luciani
Emilio SaccoEmilio Sacco
Emilio Sacco

14 February 2012 in BJU International
Verified
Journal Article
Closed access
PDF file
DTDaniele Tienforti
Daniele Tienforti
Emilio SaccoEmilio Sacco
Emilio Sacco
FMFrancesco Marangi
Francesco Marangi
ADAlessandro D'ADdessi
Alessandro D'ADdessi
MRMarco Racioppi
Marco Racioppi
PBPierfrancesco Bassi
Pierfrancesco Bassi

1 July 2009 in Urologia Internationalis
Verified
Journal Article
Open access
PDF file
Emilio SaccoEmilio Sacco
Emilio Sacco
FPFrancesco Pinto
Francesco Pinto
FSFrancesco Sasso
Francesco Sasso
MRMarco Racioppi
Marco Racioppi
GGGaetano Gulino
Gaetano Gulino
PBPierfrancesco Bassi
Pierfrancesco Bassi
Introduction: Paraneoplastic syndromes (PNS) may represent the main clinical problem in cancer patients; however, the knowledge of their clinical aspect remains quite poor among urologists. Objective: To provide urologists with an overview on main clinical aspects of PNS that have been reported to be associated to urological cancers. Methods: Literature search of peer-reviewed papers published by July 2008. Results: All genitourinary tumors can cause a PNS, and renal cell carcinoma is the most frequent urological malignancy involved. Prostate cancer is the second urological tumor associated with PNS which, conversely, are uncommon in bladder cancer and rare in testicular cancer. Tumor neuroendocrine differentiation is involved in most endocrine PNS. Neurologic PNS are very uncommon but may dominate the clinical picture and need a high suspicion index to be recognized. Important advances have been made on radionuclide scan methods in order to detect the primary tumor. The most effective treatment strategy is always represented by the radical therapy of the underlying cancer, but specific therapeutic options are sometimes available. Conclusions: Endocrine PNS are frequently associated with urological cancers, especially renal and prostate carcinoma. PNS have been rarely reported in association with cancers of bladder, urethra and testicle.